• Aucun résultat trouvé

Prévalence des manifestations rhumatologiques apparues sous immunothérapie anticancéreuse et corrélation à la réponse tumorale : une étude prospective monocentrique

N/A
N/A
Protected

Academic year: 2021

Partager "Prévalence des manifestations rhumatologiques apparues sous immunothérapie anticancéreuse et corrélation à la réponse tumorale : une étude prospective monocentrique"

Copied!
36
0
0

Texte intégral

Loading

Figure

FIGURE I – Principales thérapeutiques ciblant la costimulation
Table 2 : Demographic data, type of cancer, ICI molecules, and tumour response correlated with irAEs rheumatic irAEs (n=35) non rheumatic irAEs (n=137) no irAEs (n=368)
Figure 1 : Flow diagram for description of musculoskeletal irAEs

Références

Documents relatifs

background Immune checkpoint inhibitor (ICI)- associated early cardiac adverse events (CAEs), mostly acute and fulminant myocarditis, have been well characterized and mainly

In the cohort MYRACLE, study visits include: baseline visit, follow up visit (performed 2 months after each treatment initiation) and relapse/progression visit (per- formed at time

Concernant les deux pneumopathies mixtes, l’amplification du génome virale sur le LBA a permis l’identification d’un herpes virus et d’un rhinovirus pour deux

Investigating the effects of labor pain and pain relief with epidural analgesia on PD and PLRA may therefore be a first step to evaluate pupillometry as a tool to assess

Given the association observed between Cminss and both therapeutic efficacy and tolerability, dose individualization could be an effective approach for ipilimumab treatment in

dans quatre romans (Un an, Lac, Le Méridien de Greenwich et Je m’en vais), l’errance et la filature feront émerger deux mouvements d’écriture singuliers

Boxplots of community weighted mean of traits in living and dead testate amoeba assemblages in the Neuchâtel Botanic Garden experimental peatland (BG 2015, BG 2016) and

Given that T-Vec is able to induce an antitumor immune response in patients, several phase I clinical trials have started to evaluate the combination of this OV with